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Abstract
Introduction: T cell abnormalities have been associated with the pathogenesis of systemic sclerosis (SSc). Recently,
besides T helper (Th)17 cells, the Th22 subset has been identified in humans. Our purpose was to investigate the
pattern of cytokines produced and chemokine-receptors expressed by peripheral blood (PB) Th cells in SSc and
healthy donors (HD) focusing on cells producing interleukin (IL)-17 and IL-22 and to identify specific clinical
associations.
Methods: Clinical data and peripheral blood were collected in 33 SSc individuals and 29 HD. IL-17A, IL-22,
interferon gamma (IFN-g), IL-4 production, the chemokine receptors CCR4, CCR6, CCR10, CXCR3 expression and the
CD161 Th17 cell marker were assessed by multiparametric flow cytometry in PB CD4+ T cells. Intracellular cytokine
accumulation was further investigated in CD4+ T cells expanded in vitro for seven days.
Results: The frequency of Th22, Th17, Th2, but not Th1 cells, was significantly increased in SSc individuals
compared to HD. The percentage of CD161+CD4+ T cells was increased in SSc and correlated with the percentage
of IL-17A producing cells. Moreover, the expression of the skin- and lung-homing chemokine receptor CCR6
correlated with the frequency of IL-22 and IL-17A-producing cells in SSc but not in HD. Finally, SSc interstitial lung
disease (ILD) was strongly associated with higher numbers of IL-22 and, to a lesser extent, IL-17A-producing cells.
Conclusions: IL-22 and IL-17A-producing T cells with skin- and lung-homing capabilities are characteristically
increased in SSc. These findings support the hypothesis that Th22, in addition to Th17 cells, may be involved in
pathological processes leading to SSc. While the association between IL-22 producing cells and ILD needs to be
assessed in larger cohorts of patients, the increased frequency of Th22 cells appears to be a useful novel biomarker
in SSc.
Introduction
Systemic sclerosis (SSc), or scleroderma, is a chronic
connective tissue disease characterized by autoimmunity,
fibrosis of the skin and internal organs, and vascular
dysfunction [1]. While the pathogenic mechanisms of
the disease are still largely elusive, a number of findings
indicate that the immune response may play a key role
[2]. First, antinuclear antibodies (ANA) are
characteristically present and segregate with distinct
clinical presentations. Second, genetic studies indicate
that most of the gene polymorphisms associated with
SSc involve genes coding for molecules controlling the
immune response, shared with other auto-immune dis-
orders like systemic lupus erythematosus (SLE) [3].
Third, histological examination of the skin of patients
with SSc during the early edematous inflammatory
phase of the disease demonstrates the presence of
mononuclear cell infiltrates containing T cells with peri-
vascular distribution preceding the development of
fibrosis and overt vasculopathy [4,5]. Of interest,
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procollagen mRNA are frequently detected in areas
adjacent to mononuclear cell infiltrates suggesting that
inflammatory cells, and in particular T cells, are respon-
sible for the altered functional fibroblast phenotype [6].
Chemokine receptors sense the appropriate ligands in
the extracellular environment and transduce the signal
directing cell movement [7]. Importantly, in conjunction
with adhesion molecules, they determine the combina-
torial code used by immune cells to transmigrate across
the endothelium and reach target tissues, both in
homeostatic and inflamed conditions [8]. CCR4, and to
am o r el i m i t e dd e g r e eC C R 1 0 ,c o n t r i b u t et oh o m i n g
into the skin [9-11]. CCR6 has been shown to allow
homing into the skin and other tissues including the
lung, particularly under inflammatory conditions
[11-13]. CD4+ T cells differentiate into a variety of
effector subsets, which include T helper (Th)1, Th2,
Th17, and the more recently identified Th22 cells
[14,15]. Of interest, chemokine receptor distribution is
characteristically restricted to discrete Th cell subsets
[13,16-18]. Th1 cells mainly produce interferon gamma
(IFN-g) and are thought to preferentially express
CXCR3 [16]. Th2 cells produce interleukin (IL)-4 and
when activated preferentially express CCR4 [19]. Th17
cells produce IL-17A, IL-17F and IL-22 and mostly
express CCR6 [13]. Moreover, Th17 cells have been
recently shown to express the lectin receptor CD161,
previously known as a natural killer cell marker [20,21].
IL-22 is produced by many cell types, including Th17
cells and Th1, while Th22 cells characteristically pro-
duce IL-22 in the absence of IL-17A and IFN-g.O f
interest, Th22 are enriched in cells expressing CCR4,
CCR6, and CCR10 [17,18].
Th2 cells have been shown to be overrepresented in
SSc tissues and to be linked to active disease compared
to Th1 cells, since IL-4 has direct pro-fibrotic properties
[22-25]. While Th17 cells are thought to play an impor-
tant role in the induction of autoimmune tissue injury
[26], little is known about their role in SSc. However,
increased levels of IL-17 were detected in the sera and
bronchoalveolar lavage fluid of SSc individuals [27,28],
and in a recent study Th17 cells were found to be
increased, especially in patients with early diffuse SSc
[29]. As far as we know, no studies have yet directly
assessed the presence and the functional characteristics
of Th22 cells in SSc.
The objective of the present study was to revisit the
contribution of various CD4+ T cell subsets to the per-
ipheral cell pool characterizing SSc with major focus on
cells producing IL-22 and IL-17A. We studied the che-
mokine receptor usage for assessing their potential to
transmigrate into SSc affected tissues, and verified
whether Th cell characteristics distinguishing SSc from
healthy individuals (HD) could associate with specific
SSc clinical features. The results indicate an SSc-specific
increase in the number of Th cells producing IL-22 and
I L - 1 7 A ,s k e w e dt op r e f e r e n t i a lh o m i n gi n t ot h el u n g
and associated with interstitial lung disease (ILD).
Materials and methods
Study population
The peripheral blood of 33 consecutive SSc individuals
that satisfied the criteria by LeRoy et al.[ 3 0 ]a n dw h o
were not receiving disease-modifying drugs, cytokine
blocking reagents or immunosuppressant agents were
prospectively recruited when presenting at the Rheuma-
tology A Unit of the Cochin hospital during a nine-
month period. Their clinical characteristics are detailed
in Table 1. ILD was identified by the presence of typical
features on high-resolution computerized tomography
(HRCT) of the chest and confirmed by total lung capa-
city (TLC) lower than 80% of the predicted value. Pul-
monary artery hypertension (PAH) was suggested by an
echocardiographic systolic pulmonary arterial pressure >
40 mmHg, or a DLCO < 50% predicted in the absence
of pulmonary fibrosis or unexplained dyspnea and con-
firmed by right heart catheterization and was defined as
a mean resting pulmonary artery pressure > 25 mmHg
in the presence of a pulmonary capillary wedge pressure
£ 1 5m m H ga tr i g h th e a r tc a t h e t e r i z a t i o n .S k i ns c o r e s
were not available and cutaneous involvement was
Table 1 Clinical characteristics of the study populations
Clinical and biological features SSc (n: 33) HD (n: 29) P
Women, n (%) 29 (87.9) 23 (79.3) ns
Age, median (range) 52 (30 to
80)
50 (18 to
68)
ns
Ethnicity: Caucasian (%) 30 (90) 29 (100) ns
Diffuse cutaneous SSc, n (%) 20 (60.6) N/A
Age onset, mean (+/- SD) 44 (14) N/A
Disease duration, median (range) 7 (1 to 32) N/A
ANA positivity (%) 29 (87.9) N/A
ACA positivity (%) 4 (12.1) N/A
Anti-Scl70 positivity (%) 11 (33.3) N/A
Digital ulcers 19 (57.6) N/A
Calcinosis 9 (27.3) N/A
Arthritis 7 (21.2) N/A
PAH, n (%) 4 (12.1) N/A
ILD, n (%) 14 (42.4) N/A
Current immunosuppressive therapy
(%)
0 N/A
ANA, anti-nuclear antibodies; ACA, anti-centromere antibodies; ILD, interstitial
lung disease; PAH, pulmonary artery hypertension; N/A: not applicable. P as
determined by the Fisher’s exact test. ILD was observed on HRCT and
confirmed by a TLC < 80% of the predicted value. Pre-capillary PAH was
defined as a mean resting pulmonary artery pressure > 25 mmHg in presence
of a pulmonary capillary wedge pressure £15 mmHg by a right heart
catheterization.
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of the recruited individuals was under treatment with
immunosuppressant agents at the time of blood sam-
pling. Peripheral blood from 29 age- and sex-matched
HD was provided by the Blood Transfusion Center
(Geneva University Hospital, Switzerland) (Table 1).
This study was approved by the ethical committees of
the institutions involved and was conducted according
to the Declaration of Helsinki. Written informed con-
sent was obtained from all individuals.
Reagents
Anti-CD3 (clone OKT3) monoclonal antibody (mAb) was
obtained from American Tissue Culture Collection (Mana-
ssas, VA, USA). Anti-CD4-APC-Cy7 (clone IVT114), anti-
CD45-RA-FITC (clone HI100), anti-CCR6-PerCP-Cy5.5
(clone 11A9), anti-CCR4-PE-Cy7 (clone 1G1), anti-
CXCR3-APC (clone 1C6/CXCR3), anti-CD161-APC (clone
DX12) and anti-CD28 (clone CD28.2) mAbs came from
BD Biosciences (San Jose, CA, USA); anti-IL-4-APC (clone
8D4-8 anti-IFN-g-PE-Cy7 (clone 4S.B3) and anti-IL-17A-
FITC (clone BL168) mAbs were from Biolegend (San
Diego, CA, USA); anti-IL-22-PE (clone 142928), anti-
CCR10-PE (clone 314305) came from R&D Systems
(Abingdon, UK). The Cytofix/Cytoperm fixation/permeabi-
lization solution kit was from Becton Dickinson (San
Diego, CA, USA), Ficoll-Paque Plus from GE Healthcare
(Uppsala, Sweden), RPMI 1640, phosphate buffered saline
(PBS), glutamine, penicillin, streptomycin, trypsin, and fetal
calf serum (FCS) from Gibco (Paisley, UK), and phorbol
myristate acetate (PMA), b-mercaptoethanol and brefeldin
A from Sigma (St. Louis, MO, USA). Human T-activator
CD3/CD28 beads were obtained from Invitrogen (Oslo,
Norway) and rhIL-2 from Biogen (Cambridge, MA, USA).
Peripheral blood mononuclear cells (PBMC) culture
conditions
PBMC were cryopreserved in liquid nitrogen until use,
then thawed and maintained at 37°C for 16 h in RPMI
1640 supplemented with 1% nonessential amino acids, 1%
L-glutamine, 1% sodium pyruvate, 50 U/ml penicillin, 50
μg/ml streptomycin, 5% pooled human AB serum, 5% FCS
and 50 μM b-mercaptoethanol (complete medium) before
use. For intracellular cytokine determination, PBMC were
either cultured for 24 hours or 7 days upon activation by
CD3/CD28 cross-linking. In a 24-hour assay, brefeldin A
was added for the last 20 hours. In 7-day cultures IL-2 (20
U/ml) was added at 48 hours and the cells were re-stimu-
lated for FACS analysis with PMA/ionomycin for the last
4.5 hours, in the presence of brefeldin A.
Flow cytometry analysis
Surface staining was performed using fluorochrome-
conjugated anti-CD4, anti-CD45RA, anti-CD161, anti-
CCR6, anti-CCR4, anti-CXCR3 and anti-CCR10. In
intracellular cytokine determination, the cells were
stained with anti-CD4 mAb, fixed and incubated with
anti-IL-17A, IL-22, IFNg and IL-4 mAbs using a BD
Cytofix/Cytoperm kit according to the manufacturer’s
instruction. FACS analysis was performed on FACS-
Canto flow cytometer using FACSDiva (Becton Dickin-
son) and FlowJo softwares (Tree Star Inc. Ashland, OR,
USA). Irrelevant isotype-matched control mAb were
used to determine specific staining.
Statistical analysis
All populations satisfied the Kolmogorov-Smirnov nor-
mality test according to GraphPad Prism version 4.00
(Graphpad Software, La Jolla, CA, USA). The significant
difference between samples was computed using the
Student’s t test and correlation between variables using
the Pearson correlation coefficient. A P-value < 0.05 was
considered statistically significant. Box plots were auto-
matically generated using GraphPad. The box represents
values between 25
th and 75
th percentile with a line at
the median (50
th percentile). The whiskers extend above
and below the box to show the values at the10
th and
90
th percentiles.
Results
Increased frequency of CD4+ T cells producing IL-17A
and IL-22 in the peripheral blood of SSc individuals
Several observations support the hypothesis that T cells
are responsible for the altered phenotype of fibroblast
and endothelial cells, which ultimately leads to fibrosis
in SSc individuals [4,5,31]. We aimed at assessing
whether in the peripheral blood of a cohort of indivi-
duals affected by SSc not receiving disease-modifying
drugs, cytokine blocking reagents or immunosuppres-
sant agents, we could detect a peculiar Th cell subset
profile when compared to age- and sex-matched HD.
To assess the functional repertoire of Th cells, PBMC
from individuals affected by SSc and from HD were acti-
vated by CD3/CD28 crosslinking overnight. We then
detected the intracellular production of IL-17A, IL-22,
IFN-g and IL-4 in the CD4+ T cell fraction by multi-
parametric flow cytometry. Confirming previous data
[32,33], the frequency of CD4+ T cells was higher in
SSc than in HD (data not shown). SSc individuals had
significantly increased numbers of CD4+ T cells produ-
cing IL-4 in their lymphocyte population compared to
controls as previously shown [34], while having similar
numbers of IFN-g producing cells (Figure 1A, B). In
addition, we observed an increased number of IL-17A
and, for the first time, of IL-22 producing cells in SSc
(Figure 1B). Interestingly, subgroup analysis showed that
IL-17A-producing cells were increased in both lSSc and
dSSc, while the increase in IL-22-producing cells was
Truchetet et al. Arthritis Research & Therapy 2011, 13:R166
http://arthritis-research.com/content/13/5/R166
Page 3 of 9observed in dSSc only (Figure 1B). These data indicate
that SSc individuals compared to HD have an imbalance
in their Th cells populations.
Preferential expansion of single IL-17A+, single IL-22+
and double IL17A+IL-22+ producing CD4+ T cells in SSc
Since Th1, Th17 and Th22 cells can all produce IL-22
[35], we investigated whether in SSc individuals IL-22
was produced by the same or by distinct Th subsets. To
better discriminate these low frequency subsets, PBMC
were expanded in vitro for seven days before intracellu-
lar cytokine determination. Consistently with the results
obtained with overnight cultures, the frequency of cells
producing IL-22 was higher in SSc compared to HD
after seven-day culture. This was also true for IL-17A
(Figure 2A, B). Among all possible cytokine combina-
tions, SSc individuals had a distinct increased frequency
of IL-22 single positive (IL-17A-IL-22+IFNg-IL4-cells)
which identify the Th22 subset, and of IL-17A+IL-22+
double positive cells characteristic of Th17 cells. In
addition, IL-17A single positive cells were also increased
in SSc compared to HD (Figure 2A, C). To substantiate
such findings, we tested whether the frequency of CD4+
T cells bearing the CD161 antigen was increased in SSc,
since it has been shown that CD161 is preferentially
expressed in Th17 cells [21]. This was indeed the case
(Figure 3A) and, interestingly, CD161 expression corre-
lated with IL-17A (Pearson r = 0.47, P = 0.046) but not
IL-22 (Pearson r = 0.34, P = 0.17) production in SSc
(Figure 3Band data not shown). Of note, CD161 was
also expressed in non CD4+ cells; however, these cells
were not increased in SSc and were not correlated with
the production of IL-17A (not shown).
Altogether our data indicate a preferential expansion
of IL-22-single, IL-17A-single and IL-17A/IL-22 double
producing CD4+ T cells in SSc, thus supporting the
contention that Th22 cells in addition to Th17 cells are
expanded in SSc.
Figure 1 The number of IL-17A+ and IL-22+ CD4+ T cells is increased in SSc at Day 0. PBMC were activated by CD3/CD28 crosslinking for
24 h and surface/intracellular stained for FACS analysis. A. FACS plots gated on CD4+ T cells for representative healthy donors (HD) and SSc
individuals. Numbers in plots indicate the percentage of IL-17A, IL-22, IFN-g and IL-4 producing CD4+ T cells. B. Numbers of IL-17A, IL-22, IFN-g
and IL-4 positive CD4+ T cells for 10
4 living lymphocytes in 29 HD and 33 SSc (IL-17A, IL-22, IFN-g) or 22 HD and 23 SSc (IL-4) individuals. Shown
are significant differences assessed by unpaired t-test. lSSc, limited cutaneous SSc and dSSc, diffuse cutaneous SSc.
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in the presence of IL-2 (20 U/ml). A. FACS plots gated on CD4+ T cells of cells harvested at Day 7 of culture and activated by PMA/ionomycin
for a representative HD and SSc individual. Intracellular cytokine accumulation was detected by five-color flow cytometry. Numbers in plots
indicate the percentage of cells in each quadrant. IFN-g and IL-4 double negative cells are highlighted by grey shading. B. Frequency of IL-17A+
and IL-22+ CD4+ T cells in 29 HD and 30 SSc individuals detected by flow cytometry. C. Frequency of CD4+ T cells producing IL-17A alone (IL-
17A+IL-22-IFN-g-IL-4-cells), IL-22 alone (IL-17A-IL-22-IFN-g-IL-4-cells), and IL-17A in combination with IL-22 (IL-17A-IL-22-IFN-g-IL-4-cells) in 24 HD
and 29 SSc individuals detected by multiparameter flow cytometry analysis.
Figure 3 CD161+ CD4+ T cells are increased in SSc and correlated with the percentage of IL-17A+CD4+ T cells. A, CD4+CD161+ T cells
in the peripheral blood of SSc individuals (n = 21) and HD (n = 17) were identified by two-color flow-cytometry analysis. Bars show the means.
B, Correlation between the percentage of IL-17A+CD4+ T cells and CD161+CD4+ T cells analyzed ex vivo. For cytokine intracellular localization,
the conditions were as described in the legend of Figure 2. A two-tailed unpaired t-test (A) and Pearson correlation (B) were used for statistical
analysis.
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and IL-22-producing cells in SSc but not in HD
We then investigated whether SSc individuals had a
skewed pattern of lymphocytes expressing chemokine-
receptors involved in skin- (CCR6, CCR4 and CCR10)
[10,12] and lung-homing (CCR6) [11,13,36]. CXCR3,
preferentially expressed on Th1 cells, served as control.
The expression of CCR6, CCR4, CCR10 as well as
CXCR3 on resting peripheral blood memory CD4+ T
cells was similar in SSc and HD (Figure 4A). However,
CCR6 expression in CD4+ T cells was positively corre-
lated with the frequency of IL-17A+ and IL-22+ CD4+
T cells assessed after overnight activation (not shown).
Of note, this positive association was observed in SSc
but not in HD and was stronger with the CCR6
+CCR10- CD4+ T cell subset for both IL-17A+ (r =
0.56, P =0 . 0 1 3 )a n dI L - 2 2 +( r=0 . 5 4 ,P =0 . 0 2 4 )C D 4 +
T cells (Figure 4B). No significant positive correlations
were observed for the other Th subsets with the chemo-
kine receptors studied. Together, these data suggest that
IL-17A and IL-22-producing cells in the peripheral
blood of SSc but not HD have skin and lung-homing
properties.
The frequency of IL-22 producing CD4+ T cells
distinguishes SSc individuals according to presence of
interstitial lung disease
We finally tested whether the production of specific T
cell cytokines after overnight activation was associated
with SSc clinical characteristics. SSc individuals present-
ing with ILD, as detected by HRCT and decreased TLC,
had higher frequencies of IL-22 (P = 0.001) and IL-17
producing T-cells (P = 0.05) (Figure 5) when compared
with those without ILD. Moreover, IL-4 producing T-
cells showed a trend to increase in SSc individuals
having ILD (P =0 . 0 8 ) ,w h i l eI F N - g producing T-cells
did not (Figure 5). Of interest, no differences were
observed in the frequencies of cytokine producing cells
when considering the gender, lSSc vs. dSSc, disease
duration, presence of digital ulcers or PAH, and ANA
positivity thus reinforcing the specificity of our finding.
Discussion
In the present study, we demonstrate that Th22 and
Th17 cells are specifically increased in the peripheral
blood of individuals affected by SSc compared to HD.
Moreover, the number of IL-17A and IL-22-producing
T cells correlated with CCR6 expression in SSc and not
in HD, consistent with enhanced skin- and lung-homing
properties for these cells under inflammatory conditions.
In addition, we identified a strong relationship between
high numbers of IL-22 producing T-cells and SSc ILD.
The relatively low number of individuals included lim-
its the power of our study. In addition, we did not have
data on disease activity and quantitative evaluation of
the skin involvement. However, our cohort was prospec-
tively recruited and the patients included were not
receiving disease-modifying drugs, cytokine blocking
reagents or immunosuppressant agents at the time of
sampling, which strengthen the reliability of our
findings.
By applying a multi-parameter cytofluorimetric analysis
we found an increased number of CD4+ T cells producing
IL-17A and IL-22 in SSc. They were identified as bona fide
Th17 and Th22 cells, since single IL-17A+ cells (IL-17A
+IL-22-IFNg-IL4-), single IL-22+ cells (IL-17A-IL-22
+IFNg-IL4-), in addition to double IL-17A+IL-22+ cells
(IL-17A+IL-22+IFNg-IL4-) were distinctly increased in
SSc upon seven days of culture. Although unlikely, we
cannot exclude that a small percentage of NKT cells or g/δ
Figure 4 IL-17A and IL-22 production correlates with CCR6+CCR10- expression in SSc CD4+ T cells. A. Frequency of CD4+CD45RA- T cells
expressing CXCR3, CCR6, CCR4 or CCR10 in SSc and in HD detected by a six-color flow cytometry. Columns represent mean ± SD. B. Correlation
between the percentages of IL-17+ CD4+ T cells or IL-22+ CD4+ T cells with CCR6+CCR10- in CD4+CD45RA- T cells. Full and empty dots
represent SSc and HD, respectively. Continuous and dotted regression lines correspond to SSc and HD, respectively. Pearson correlation was
used for statistical analysis.
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IL-22 production in our culture system.
Noteworthy, in SSc, and not in HD, the IL-22 and IL-
17A T cell numbers strongly correlated with the expres-
sion of CCR6, particularly in the absence of CCR10,
which may indicate that these cells are prone to be
recruited into inflamed target tissues, specifically in SSc,
including the lung. Furthermore, we show for the first
time that CD4+ T cells expressing the lectin receptor
CD161 are increased in SSc and positively correlate with
the number of Th17 cells [20].
Our study is the first to assess the presence and func-
tional characteristics of Th22 cells in SSc. It is
interesting to note that Th22 cells appear to play impor-
tant roles in inflammatory skin disorders. For instance,
the frequency of IL-22+ T cells in skin derived T-cell
lines from psoriasis, atopic eczema and allergic contact
dermatitis was significantly higher than in the peripheral
blood [17,37-39]. Furthermore, supernatants of skin-
derived Th22 clones from psoriatic lesions enhanced
wound healing in an in vitro injury model, and tran-
scriptome profiling of epithelial cells submitted to the
influence of these clones revealed up-regulation of genes
involved in tissue remodeling, angiogenesis and fibrosis
[37]. In our cohort of SSc, we found that SSc individuals
presenting with ILD had increased numbers of IL-22
Figure 5 Increased frequency of IL-22 producing cells in SSc individuals presenting with interstitial lung disease. Frequency of IL-17A,
IL-22, IFN-g and IL-4 producing CD4+ T cells in SSc individuals presenting or not with ILD. A two-tailed, unpaired t-test was used for statistical
analysis.
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possible mechanisms underlying this association. For
instance, lung inflammation was ameliorated in IL-22-
deficient mice receiving high doses of bleomycin com-
pared to IL-22-sufficient mice [40]. On the other hand,
protection mediated by IL-22 produced by gamma/delta
T cells has been reported in a mouse model of lung
fibrosis induced by hypersensitivity to Bacillus subtilis
[41]. While it remains to be established whether the par-
ticipation of Th22 cells in SSc pathogenic events is
harmful rather than protective, their association with
ILD suggests an important function of these cells.
Consistent with our findings, IL-17 was previously
shown to be increased in the serum and the bronch-
oalveolar lavage fluid of SSc individuals [27,28]. In
addition, an increase in Th17 cells in the peripheral
blood of SSc was recently reported [29]. What could
be the contribution of IL-17 to SSc pathogenesis
remains at the moment speculative. IL-17A has been
reported to induce IL-6 and IL-8 production and inter-
cellular adhesion molecule 1 (ICAM-1) expression in
human fibroblasts [42]. It should be noticed that IL-
1 7 Ah a sb e e ns h o w nt op a r t i c i p a t ei na nI L - 1 - d e p e n -
dent manner to the development of bleomycin-induced
mouse lung fibrosis [43] and IL-17 may directly stimu-
late collagen synthesis in rodent fibroblasts [44,45].
However, Kurasawa and colleagues could not demon-
strate an increased synthesis of type I and III collagen
mRNA in human dermal fibroblasts activated by IL-17
[27]. The different responses of mouse and human
fibroblasts to IL-17 may be explained by species-speci-
fic characteristics. Thus, our data are in line with the
hypothesis that Th17 cells in SSc could be more
related to inflammation, autoimmunity, and possibly
the generation of autoantibodies [46], as it is specu-
lated for several autoimmune disorders non-character-
ized by fibrosis, including systemic lupus
erythematosus and rheumatoid arthritis in which Th17
cells are increased [26,47,48].
Conclusions
SSc individuals have an increased frequency of circulat-
ing IL-22 and IL-17A, producing cells with skin- and
lung-homing potential. The association we found
between increased numbers of IL-22-producing cells
and ILD indicate that Th22 may act as biomarkers to
identify individuals at risk and need to be assessed in
larger prospective cohorts of patients.
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